Immunitybio Inc (IBRX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Immunitybio inc   (NASDAQ: IBRX)


Immunitybio Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Immunitybio Inc's ROI in the second quarter of 2026?
Immunitybio Inc recorded a cumulative net loss of $-992 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -195.06%.

Within the Healthcare sector 187 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 4107 to 4114.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 63.94 % 44.29 % 10.77 % -5.62 % -18.41 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 552 580 441 463 352
Return On Investment (TTM) -195.06 % -186.22 % -93 % -99.66 % -118.31 %
IBRX's Overall Ranking # 4114 # 4107 # 2869 # 3585 # 3190
Seq. Investment Change TTM 10.86 % 21.44 % 8.01 % 12.74 % -2.43 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -992 -855 -351 -349 -367

IBRX Company Profile >> Back to IBRX Roi Comparisons >> See Annual IBRX Return On Investment



Return On Investment IBRX's Ranking
Within: No.
Industry # 20
Sector # 188
Overall # 4114

Return On Investment Statistics
High Average Low
-34.72 %
-213.19 %
-1966.36 %
(Sep 30 2017)   (Dec 31 2022)



  News about Immunitybio inc Return on Investment ROI

ImmunityBio Reports Promising Results in BCG-Unresponsive NMIBC CIS Trial as Shares Underperform Market

November 19, 2024

Culver City, Calif. ImmunityBio, Inc. (NASDAQ: IBRX), a pioneering company in the field of immunotherapy, has successfully completed the post-approval enrollment of the 100th patient in its ANKTIVAs clinical trial targeting Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). As of November 2024, the QUILT 3.032 study has shown a remarkable complete response (CR) rate of 71%, with these responses demonstrating a durable duration of up to 54 months.The QUILT 3.032 study combines ImmunityBio s lead investigational agent, ANKTIVA (nogapendekin alfa inbakicept-pmln), with BCG, a standard treatment for bladder cancer. This innovative approach aims to enhance patient outcomes in a demographic that typically has limited responses to existing therapies. The study’s robust findings provide optimism for the future treatment landscape of NMIBC.





Financial Statements
Immunitybio Inc's II. Quarter Investments $ 552 Millions IBRX's Balance sheet
Immunitybio Inc's II. Quarter Income $ -230 Millions Quarterly IBRX's Income Statement
IBRX's Income by Division See IBRX's Income by Division


IBRX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 441 329 447 -141 98
Y / Y Investment Growth 34.07 % -26.44 % - - -22.82 %
Net Income in Millions -351 -414 -584 -417 -350
Y / Y Net Income Growth - - - - -
Annual Return On Investment -79.69 % -125.74 % -130.55 % - -356.35 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
IBRX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for IBRX's Competitors
Subscribers only: Roi for Immunitybio Inc's Suppliers
Subscribers only: Return On Investment for IBRX's Customers

Other Ratios
IBRX's Roa IBRX's Inventory Turnover Ratio IBRX's Growth Rates IBRX's Dividend Statistics
IBRX's Profitability Ratios IBRX's Asset Turnover Ratio IBRX's Dividend Growth
IBRX's Roe IBRX's Valuation Ratios IBRX's Financial Strength Ratios IBRX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-08-30T21:40:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.